Novo Nordisk Raises 2026 Outlook on Wegovy Pill Sales
Novo Nordisk raised its full-year outlook for the third time as strong Wegovy pill sales beat expectations. The Danish drugmaker is working to regain ground from rival Eli Lilly. Adjusted operating profit reached 31.72 billion crowns.
Xurve View
Insights:
Xurve View
NOVO NORDISK A/S-B raised its 2026 outlook on Wednesday as its oral Wegovy treatment beat third-quarter sales estimates, pushing shares up 5% in European trading.
